Image

Global Tofacitinib Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Tofacitinib Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Tofacitinib Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 2.34 USD Billion
Diagram Market Size (Forecast Year) USD 5.67 USD Billion
Diagram CAGR %

Major Markets Players

  • Beacon Pharmaceuticals Limited
  • Pfizer
  • Globe Pharmaceuticals
  • Delta Pharma Limited
  • DRUG INTERNATIONAL LTD

Global Tofacitinib Market, By Strength (5mg, 10mg, 11mg, and 22mg), Drug Class (Antirheumatic, Janus Kinase Inhibitor, and Immunosuppressant), Application (Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, and Others), Demographic (Adult, Pediatric, Geriatric), Dosage Form (Tablet, Solution, Tablet, Extended Release, and Others), Route of Administration (Oral and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.

Tofacitinib Market

Tofacitinib Market Analysis and Size

Tofacitinib, commonly known as Xeljanz, belongs to the Janus Kinase (JAK) inhibitor class of drugs. It works by inhibiting the activity of Janus kinase enzymes, which are implicated in the inflammation that triggers rheumatoid and psoriatic arthritis symptoms. Tofacitinib is also used to treat moderate to severe ulcerative colitis in individuals who cannot take certain drugs or have failed to respond to other treatments.                

Data Bridge Market Research analyses that the tofacitinib market, which was USD 2.34 billion in 2022, would rocket up to USD 5.67 billion by 2030 and is expected to undergo a CAGR of 4.7% during the forecast period of 2023 to 2030. “Antirheumatic” dominates the drug class segment of the market owing to the rise in the incidence of autoimmune disorders among the population.

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Tofacitinib Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Strength (5mg, 10mg, 11mg, and 22mg), Drug Class (Antirheumatic, Janus Kinase Inhibitor, and Immunosuppressant), Application (Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, and Others), Demographic (Adult, Pediatric, Geriatric), Dosage Form (Tablet, Solution, Tablet, Extended Release, and Others), Route of Administration (Oral and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

Countries Covered

U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa

Market Players Covered

  • Beacon Pharmaceuticals Limited (Bangladesh), Pfizer Inc. (U.S.), Globe Pharmaceuticals (Egypt), Delta Pharma Limited (Bangladesh), DRUG INTERNATIONAL LTD. (Bangladesh), Mediconlife, Dolphin Pharma (U.S.), Lancer Therapeuticals (India), Aprazer (India), Glenmark Pharmaceuticals Limited (India), Sun Pharmaceutical Industries Ltd. (India), Shandong Octagon Chemicals Limited (China), APINO PHARMA CO., LTD. (China), Zydus Cadila (India), Beijing Mesochem Technology Co., Ltd. (China), Olon S.p.A. (Italy), Unichem Laboratories (India), and Esteve Química (France) among others

Market Opportunities

  • Rising technological advancements and innovations
  • Growing demand for personalized medicine
  • Increasing awareness and early diagnosis

Market Definition

The medications known as Janus Kinase (JAK) inhibitors include tofacitinib. It is used to treat several autoimmune conditions, most notably ulcerative colitis, psoriatic arthritis, and rheumatoid arthritis.

Tofacitinib Market Dynamics

Drivers

  • Increasing prevalence of autoimmune diseases

The increased prevalence of autoimmune illnesses such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis primarily drives the tofacitinib market. The demand for efficient medications such as tofacitinib keeps rising because these conditions impact a sizable section of the world's population.

  • Rising geriatric population

As autoimmune illnesses are more common in the elderly, tofacitinib and other drugs used to treat these conditions are projected to be in high demand as the world's elderly population grows.

  • Increasing R&D activities

The market for tofacitinib is growing due to ongoing research and development projects in the areas of autoimmune disorders and JAK inhibitors. Tofacitinib can be used to treat various autoimmune diseases, and pharmaceutical companies are exploring this possibility and investing in creating new formulations, which are expected to drive market growth.

Opportunities

  • Growing  demand for personalized medicine

Personalized medicine and genetics development presents prospects for modifying therapy for specific patients. The treatment plans can be created by identifying the genetic differences and biomarkers linked to the response to tofacitinib. Tofacitinib's effectiveness can be increased using personalized medicine strategies, which pharmaceutical companies can explore through partnerships and collaborations with diagnostic businesses.

  • Rising technological advancements and innovation

It is envisaged that improvements in tofacitinib development will result in improved formulations, enhanced drug delivery methods, and novel methodologies. These developments are meant to increase medicine effectiveness, patient compliance, and administration convenience.

  • Increasing awareness and early diagnosis

In recent years, autoimmune illnesses have received better diagnoses and more attention. As a result, more individuals are seeking medical care and getting accurate diagnoses, which raises the need for drugs like tofacitinib.

Challenges/ Restraints

  • Strict regulations

Drug approval is subject to strict regulatory standards, particularly in terms of safety and efficacy. The time and money required to meet these regulatory requirements and get permits may delay market entry and limit market growth.

  • Adverse effects and safety concerns

Tofacitinib has potential adverse effects, similar to any medication, including an increased risk of infections, changes in blood cell counts, abnormalities in liver enzymes, and elevated cholesterol levels. Tofacitinib's acceptance and uptake may be impacted by safety worries and adverse effects, particularly in patient demographics or among more risk-averse healthcare professionals.

  • Reimbursement policies

Various nations and healthcare systems have different pricing and reimbursement practices. For pharmaceutical firms, establishing favorable pricing agreements and reimbursement coverage can be difficult, particularly in areas with healthcare systems that are cost-conscious. Pricing pressures may restrict market access and have an impact on tofacitinib usage.

  • High Costs of Drugs

Tofacitinib's price and patients' capacity to pay it might be very difficult, especially in areas with insufficient healthcare resources or where reimbursement coverage is restricted. Access and adoption may be hampered by high treatment costs, especially in lower-income communities. For the market to expand, it is crucial to address cost issues and investigate pricing plans that balance accessibility and sustainability.

This tofacitinib market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tofacitinib market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Tofacitinib Market Scope

The tofacitinib market is segmented on the basis of strength, drug class, application, demographic, dosage form, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Strength

  • 5mg
  • 10mg
  • 11mg
  • 22mg

Drug Class

  • Antirheumatic
  • Antirheumatic disease modifying
  • Antirheumatic miscellaneous
  • Janus kinase inhibitor
  • Immunosuppressant

Application

Demographic

  • Adult
  • Pediatric
  • Geriatric

Dosage form

  • Tablet
  • Solution
  • Extended release
  • Others

Route of Administration

  • Oral
  • Others

End Users

  • Hospital
  • Clinic
  • Others

Distribution channel

  • Hospital pharmacy
  • Online pharmacy
  • Retail pharmacy

Tofacitinib Market Regional Analysis/Insights

Tofacitinib market is analyzed and market size information is provided by the country, strength, drug class, application, demographic, dosage form, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the tofacitinib market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.

North America is expected to dominate the market due to the presence of major key players, high disposable income, and well-developed healthcare infrastructure in this region.

Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities and the rise in the prevalence of rheumatoid arthritis in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

Tofacitinib market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Tofacitinib Market Share Analysis

Tofacitinib market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to tofacitinib market research.

Some of the major players operating in the tofacitinib market are:

  • Beacon Pharmaceuticals Limited (Bangladesh)
  • Pfizer Inc. (U.S.)
  • Globe Pharmaceuticals (Egypt)
  • Delta Pharma Limited (Bangladesh)
  • DRUG INTERNATIONAL LTD. (Bangladesh)
  • Mediconlife, Dolphin Pharma (U.S.)
  • Lancer Therapeuticals (India)
  • Aprazer (India)
  • Glenmark Pharmaceuticals Limited (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Shandong Octagon Chemicals Limited (China)
  • APINO PHARMA CO., LTD. (China)
  • Zydus Cadila (India)
  • Beijing Mesochem Technology Co., Ltd. (China)
  • Olon S.p.A. (Italy)
  • Unichem Laboratories (India)
  • Esteve Química (France)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Tofacitinib Market will be worth USD 5.67 billion by 2030
The Tofacitinib Market Growth Rate is 4.7% during the forecast period.
The Increasing R&D activities, Rising geriatric population, and Increasing prevalence of autoimmune diseases are the Growth drivers of the Tofacitinib Market.
The strength, drug class, application, demographic, dosage form, route of administration, end-users, and distribution channel are the factors on which the Tofacitinib Market research is based.
The major comapnies in the tofacitinib market are Beacon Pharmaceuticals Limited ,Pfizer Inc., Globe Pharmaceuticals, Delta Pharma Limited ,DRUG INTERNATIONAL LTD.,Mediconlife, Dolphin Pharma, Lancer Therapeuticals, Aprazer ,Glenmark Pharmaceuticals Limited , Sun Pharmaceutical Industries Ltd.,Shandong Octagon Chemicals Limited ,APINO PHARMA CO., LTD. , Zydus Cadila , Beijing Mesochem Technology Co., Ltd., Olon S.p.A, & Unichem Laboratories.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials